Chronic lymphocytic leukaemia trials in Austria

7 of 10 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.

• Phase 4Not yet taking people in Austria
  A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  Where

  Salzburg

  Age

  18 years and over

  People

  150 worldwide

  Run by

  Eli Lilly and Company

  See details and how to joinNCT07218341
• Phase 3Taking people
  A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  Where

  Innsbruck, Vienna

  Age

  18 years and over

  People

  630 worldwide

  Run by

  BeOne Medicines

  See details and how to joinNCT06943872 · EU 2024-517131-52-00
• Phase 2Taking people
  MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab

  Where

  Horn

  Age

  18 years to 130 years

  People

  80 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT07024706 · EU 2024-518858-17-00
• Phase 3Taking people
  A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)

  Where

  Graz, Innsbruck, Vienna

  Age

  18 years and over

  People

  746 worldwide

  Run by

  University Of Cologne

  See details and how to join2023-510294-34-00
• Phase 3Taking people
  A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  Where

  Graz, Innsbruck, Linz, Salzburg, St. Poelten

  Age

  18 years and over

  People

  500 worldwide

  Run by

  BeOne Medicines

  See details and how to joinNCT06973187 · EU 2025-522860-34-00
• Phase 3Completed
  A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  Where

  Linz, Vienna

  Age

  18 years and over

  People

  737 worldwide

  Run by

  Loxo Oncology, Inc.

  See details and how to joinNCT05254743 · EU 2023-507699-38-00
• Phase 2Taking people
  Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

  Where

  Leoben, Linz, St. Poelten, Vienna

  Age

  18 years and over

  People

  75 worldwide

  Run by

  AbbVie

  See details and how to joinNCT04895436 · EU 2023-504599-10-00